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The potential of liquisolid systems to improve the disso-
lution properties of a water-insoluble agent (indometha-
cin) was investigated. In this study, different formulations
of liquisolid tablets using different co-solvents (non-vola-
tile solvents) were prepared and the effect of aging on
the dissolution behaviour of indomethacin liquisolid com-
pacts was investigated. To evaluate any interaction be-
tween indomethacin and the other components in liqui-
solid formulations, X-ray powder diffraction (XPD) and
differential scanning calorimetry (DSC) were used. Dis-
solution test was carried out at two different pH, 1.2 and
7.2, to simulate the stomach or intestine fluid, respectively.
The results showed that liquisolid formulations exhibited
significantly higher drug dissolution rates at pH 1.2 and
7.2 compared to compacts prepared by the direct com-
pression technique. The enhanced rate of indomethacin
dissolution from liquisolid tablets was probably due to
an increase in wetting properties and surface area of drug
particles available for dissolution. In order to investigate
the effect of aging on the hardness and dissolution rate
of liquisolid compacts, the formulations were stored at 25
°C/75% relative humidity for a period of 12 months. The
results showed that aging had no significant effect on disso-
lution profiles of liquisolid tablets. Liquisolid compacts
containing propylene glycol as vehicle produced higher
dissolution rates in comparison with liquisolid compacts
containing PEG 400 or Tween 80 of the same concentra-
tion. The DSC and XPD results showed no changes in crys-
tallinity of the drug and interaction between indometha-
cin and excipients (Avicel and silica) during the process.
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Poorly water-soluble drugs (such as indomethacin) involve many difficulties in the
development of pharmaceutical dosage forms for oral delivery systems due to their low
bioavailability. It has been established that the active ingredient in a solid dosage form
must undergo dissolution before it is available for absorption from the gastrointestinal
tract. The rate of absorption of a poorly water-soluble drug, formulated as an orally ad-
ministered solid dosage form, is controlled by its dissolution rate in the fluid present at
the absorption site, i.e., the dissolution rate is often the rate-determining step in drug ab-
sorption. Therefore, the solubility and dissolution behavior of a drug are the key deter-
minants of its oral bioavailability. Many methods are available to improve these charac-
teristics, including (i) reducing the particle size to increase surface area, thus increasing
the drug dissolution rate; (ii) solubilization in surfactant systems; (iii) formation of wa-
ter-soluble complexes; (iv) use of pro-drug and drug derivatization such as strong elec-
trolyte salt forms that usually have higher dissolution rates; and (v) manipulation of the
solid state of a drug substance to improve drug dissolution, i.e., by decreasing crystal-
linity of the drug substance through formation of solid solutions (1). The most common
method is to increase the drug surface area by micronization. But, in practice, the effect
of micronization is often disappointing, especially when the drugs are encapsulated or
tableted (2–4). The most promising method for promoting dissolution is the formation of
liquisolid tablets (5–7).
Formulating liquid medications into solid compacts has been the object of many
studies. Jarowski (8, 9) and Spireas et al. (5–7) worked on producing solid solutions and
»liquisolids« based on the concept of blending liquid medications with selected powder
excipients to produce free flowing, readily compressible powders.
A »liquisolid system« refers to formulations formed by conversion of liquid drugs,
drug suspensions or drug solution in non-volatile solvents, into dry, nonadherent, free-
-flowing and compressible powder mixtures by blending the suspension or solution with
selected carriers and coating materials (5). Various grades of cellulose, starch, lactose,
etc., may be used as the carrier, whereas very fine particle size silica powder may be used
as the coating material.
The anti-inflammatory agent indomethacin exhibits poor solubility. This undesirable
physical property may increase the incidence of irritating side effects on the gastrointes-
tinal tract because of a prolonged contact time with the mucosa. In our previous study
(10), it was shown that indomethacin liquisolid compacts demonstrated considerably
higher drug dissolution rate than those of conventional capsules and directly compres-
sed tablets. In this study, the effects of aging and types of vehicle on the hardness and
dissolution profile of indomethacin liquisolid compacts were investigated. Interaction
between the drug and excipients, and crystalinity changes, if any, in liquisolid formula-
tions were also studied using X-ray powder diffraction (XPD) and differential scanning
calorimetery (DSC).
EXPERIMENTAL
Materials
Indomethacin was provided by Industrial Shahid Razakani (Iran). Coarse granular
microcrystalline cellulose (Mingtai Chemical, Taiwan), sodium starch glycolate (Yung
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Zip Chemical, Taiwan), nm-sized amorphous silicon dioxide (Mingtai Chemical) and
Tween 80, lactose, starch, sorbitol and sodium chloride (Merck, Germany) were used.
Spectrophotometric analysis
The spectrophotometric analysis of all indomethacin samples in aqueous solutions
(pH 1.2 or 7.2) was performed at 318 nm (UV/Visible spectrophotometer, Shimadzu-120,
Japan). Standard curves were constructed by serially diluting an aqueous stock solution
of the drug (at pH 1.2 and 7.2) to obtain concentrations in the range of 2.5–50 mg mL–1
using simulated gastric fluid (SGF) or simulated intestine fluid (SIF) as diluents. Each
sample was analyzed in triplicate.
Preparation of conventional tablet and liquisolid compacts
Indomethacin conventional tablets were produced by mixing the drug (2.5 g) with a
microcrystalline cellulose-silica mixture (ratio of microcrystalline cellulose/silica was 20:1
and the amounts of microcrystalline cellulose and silica were 10 g and 0.5 g, respectively)
for a period of 10 min in a small cubic mixer. The mixture was mixed with sodium starch
glycolate (as disintegrating agent) for 10 min, and compressed on a 10-mm punch and die
using a manual-tableting machine (Riken, Japan). Sufficient compression load was appli-
ed in order to produce tablets with the hardness of 42–56 N. This formulation was de-
noted as DCT. The same formulation was usual to produce capsule formulation for com-
parison purposes. Then each tablet and capsule contained 25 mg indomethacin, 100 mg
microcrystalline cellulose, 5 mg of nm-sized silica and 5 mg sodium starch glycolate.
Several liquisolid compacts (denoted ILS-1 to ILS-3) were prepared as follows. In-
domethacin (20 g) was dispersed in a nonvolatile vehicle (propylene glycol, Tween 80 or
PEG 400). Then a binary mixture of carrier-coating materials (microcrystalline cellulose
as the carrier powder and silica as the coating material at a ratio of 20:1) was added to
the mixture containing the drug and propylene glycol under continuous mixing in a
mortar. Depending upon the type of vehicle in the formulation, different liquid loading
factors were employed in our liquisolid preparations (the liquid loading factor, Lf, is the
mass ratio of the liquid medication and carrier powder in the liquidsolid formulation).
Therefore, different concentrations of avicel and silica were used to prepare different
liquisolid formulations. For example, to prepare different batches of liquisolid powders,
the amounts of avicel were 418, 476.2 and 444.4 g mixed with 20.9, 23.8, and 22.22 g sil-
ica for ILS-1, ILS-2 and ILS-3, respectively. Finally, 5% (m/m) of sodium starch glycolate,
as disintegrant, was mixed with the mixture for a period of 10 min. The final mixture
was compressed using the manual tableting machine to achieve tablet hardness of 42–56
N. Important formulation characteristics of the prepared indomethacin liquisolid com-
pacts are shown in Table I.
Dissolution studies
The USP paddle method was used for all the in vitro dissolution studies (11). Water
containing HCl, which simulated gastric fluid without pepsin (pH 1.2) or intestinal fluid
without pancreatin (phosphate buffer pH 7.2), were used as dissolution media. The rate of
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stirring was 100 ± 2 rpm. The amount of indomethacin was 25 mg in all formulations. The
dosage forms were placed in 900 mL of gastric fluid (HCl solution) or intestinal fluid (phos-
phate buffer pH 7.2) and maintained at 37 ± 0.1 °C. At appropriate intervals (10, 20, 30 and
60 min), 5 mL of the samples were taken and filtered through a 0.45 mmMillipore filter. The
dissolution medium was then replaced by 5 mL of fresh dissolution fluid to maintain a con-
stant volume. The samples were then analyzed at 318 nm. The mean of 3 determinations
was used to calculate the drug release from each formulation.
For assessment and comparison of dissolution profiles, the similarity factor (f2) (12)
was calculated. Results are quoted as significant where f2 < 50.
To compare the effects of the type of cosolvent on the drug release, mean dissolu-
tion time (MDT) (13) and dissolution efficiency (DE) (14) were used. Mean dissolution
time is as described below:
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where j is the sample number, n is the number of dissolution sample times, t is the
time at the midpoint between t and t–1 (easily calculated with (t + t–1)/2) and DMj is the
additional amount of drug dissolved between t and t–1.
DE is as described below:
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where Y is the percent drug released as a function of time, t is the total time of drug
release and Y100 is 100% drug release.
X-ray powder diffraction
The cavity of the metal sample holder of the X-ray diffractometer was filled with
ground sample powder and then smoothed with a spatula. X-ray diffraction pattern of
102
Y. Javadzadeh et al.: Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical
properties, Acta Pharm. 57 (2007) 99–109.
Table I. Key formulation characteristics of the prepared indomethacin liquisolid compacts
Liquisolid
system
Non-volatile
solvent
Carrier
Drug concentration
in liquid medication
(%, m/m)
Liquid load
factor (Lf)
Unit dose
(mg)
ILS-1 Propylene glycol Avicel 20 0.240 707.2
ILS-2 Tween 80 Avicel 20 0.210 789.4
ILS-3 PEG 400 Avicel 20 0.225 745.6
Brought to you by | University of Sussex
Authenticated
Download Date | 1/6/15 3:04 PM
indomethacin samples was obtained using the X-ray diffractometer (Siemens, Model D5000,
Germany) at 40 kV, 30 mA and a scanning rate of 0.6 min–1 over the range 5–70 2q, using
CuKa1 radiation of wavelength 1.5405 Å.
Differential scanning calorimetry
Thermograms of samples (indomethacin, excipients physical mixtures of conventi-
onal formulations and liquisolid formulations) were recorded on a DSC-60 (Shimadzu,
Japan). Samples (3–5 mg accurately weighed to 0.005 mg) were placed in aluminum pans
and the lids were crimped using a Shimadzu crimper. Thermal behavior of the samples
was investigated at a scanning rate of 10 °C min–1, covering a temperature range of 30–
300 °C. The instrument was calibrated with an indium standard.
Statistical analysis
All the data were statistically analyzed using a t-test of unknown variance.
RESULTS AND DISCUSSION
To investigate the effect of vehicle type on the rate of indomethacin dissolution from
liquisolid compacts, several formulations were prepared with polyethylene glycol (ILS-1),
Tween 80 (ILS-2) and PEG 400 (ILS-3) containing 20% (m/m) of indomethacin in liquid
medication. The dissolution profiles of these liquisolid compacts at different pH (1.2 and
7.2) are shown in Fig. 1. It can be seen from Fig. 1 that all three liquid medications (PG,
Tween 80 and PEG 400) used in liquid solid compacts, are able to increase the dissolu-
tion rate of indomethacin from liquisolid compacts in comparison with the conventional
tablet (DCT) or capsule formulations. According to Fig. 1, liquisolid compacts containing
propylene glycol produced higher dissolution rates compared to other liquisolid com-
pacts containing PEG 400 or Tween 80 of the same concentration. For example, amounts
of the drug released from formulations in 10 min in the presence of PG, PEG 400 or Twe-
en 80 were 34, 28 and 27 and 99, 90 and 87% at pH 1.2 and 7.2, respectively. This is due
to different solubility of indomethacin in liquid medications (10).
To compare the dissolution data, dissolution efficiency (DE) and mean dissolution
time (MDT) were used. The results of fitting the dissolution data with these dissolution
criteria are shown in Table II. The values of DE are consistent with the dissolution data.
For example, the DE values for the conventional tablets and capsules at pH 1.2 are 8.9
and 10.4%, respectively, whereas this value increased to 35.8, 32.2 and 30.0% for liqui-
solid compacts containing PG, PEG 400 and Tween 80, respectively. A similar trend was
obtained at pH 7.2. The results show that within the formulation series DE values in-
creased as the pH of the dissolution medium increased. This is due to higher indome-
thacin solubility at higher pH. Table II also shows that MDT was considerably lower for
the liquisolid formulation, indicating a faster dissolution rate for these formulations com-
pared to the conventional formulations.
It has been shown that polymorphic changes of the drug are important factors, which
may affect the dissolution rate and bioavailability (15). It is therefore important to study
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the polymorphic changes of indomethacin in liquisolid formulations. Fig. 2 shows the
X-ray diffractograms of pure indomethacin and pure excipients, a physical mixture of
the conventional formulation (indomethacin, avicel and silica) and liquisolid formula-
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Fig. 1. Effect of the type of vehicle on the
dissolution profile of indomethacin liqui-
solid compacts (mean ± SD, n = 3).
Table II. Mean dissolution time (MDT) and dissolution efficiency (DE) of liquisolid
formulations and conventional formulations
Formulation code
DE (%) MDT (min)
pH 1.2 pH 7.2 pH 1.2 pH 7.2
DCT 8.9 58.0 11.0 13.6
Capsule 10.4 60.3 9.3 14.3
LS-1 35.8 91.2 9.0 5.2
LS-2 32.2 88.7 9.6 6.2
LS-3 30.0 88.6 9.2 6.8
LS-1-ageda 37.2 92.1 8.1 5.1
a LS-1 stored at 25 °C/75% relative humidity for a period of 12 months.
Brought to you by | University of Sussex
Authenticated
Download Date | 1/6/15 3:04 PM
tion. Indomethacin diffractogram showed sharp peaks at 10.2, 11.6, 17.0, 19.6, 20.8, 21.8,
24.0, 26.2 and 29.5 2q. This corresponds to the g polymorph of indomethacin (16–19). As
it is clear from Fig. 2, liquisolid and physical mixture formulations have the same dif-
fraction pattern and there were no peaks other than the peaks of avicel and indometha-
cin. It was shown that two environmental factors (temperature and relative humidity)
can alter the crystal form of indomethacin (20, 21). Below Tg of indomethacin, only the
most stable g-crystal form of indomethacin appeared, whereas above Tg, both the unsta-
ble a-crystal form and the g-form appeared, with the a-form dominating as the tempera-
ture was raised above 60 °C. Imaizumi et al. (21) reported that the exposure of indome-
thacin to 69 and 79% RH produced only g-crystal forms, whereas exposure to 89% RH
produced a mixture of a- and g-forms and 100% RH produced the a-form only. The re-
sults showed that Tg of indomethacin in the present study was 42 °C, which is well abo-
ve the preparation conditions of liquisolid powders (25 °C/60% RH) in this study. As
the liquisolid compacts were prepared at 25 °C/60% RH, so according to the above in-
formation, it is unlikely that these conditions would convert the g-form to a-form.
DSC thermograms confirmed the above findings (Fig. 3). Indomethacin showed an
endothermic peak around its melting point. The liquisolid and physical mixture formu-
lations showed the same peak in this area, which indicates that there is no interaction
between the drug and excipients or changes in crystallinity of the drug during the for-
mulation process. From the above finding it can be concluded that the enhanced dissolu-
tion rate of indomethacin liquisolid compacts is not due to the formation of a complex
between the drug and excipients or any changes in crystallinity of the drug.
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Fig. 2. X-ray powder diffractions of: a) indomethacin, b) liquisolid formulation,
c) physical mixture of conventional formulation, d) Avicel, e) silica.
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In order to study the effect of aging on the hardness and dissolution profile of in-
domethacin liquisolid compacts, the best formulation (ILS-1, containing PG) was selected
and 6 tablets from the ILS-1 series were kept at 25 °C/75% relative humidity for a period
of 12 months. Hardness and dissolution tests were then performed on these tablets. The
results showed that the hardness of ILS-1 tablets at the beginning and after 12 months
were 45.2 ± 2.9 and 40.9 ± 4.3 N (n = 6), respectively, indicating that there was no signifi-
cant difference between the hardness of fresh and aged tablets. Due to good compacti-
bility of the produced liquid solid formulations, it is possible to prepare liquid solid com-
pacts using high initial pressure to retain the hardness of final tablets in an acceptable
range.
Fig. 4 shows the dissolution profile of freshly made liquisolid tablets and those stor-
ed for 12 months at 25 °C/75% relative humidity. Respective DE and MDT data at pH
1.2 for the freshly made liquisolid compacts (ILS-1) were 35.8% and 9 min and for aged
liquisolid tablets (ILS-1 aged) 37.2% and 8.1 min indicating no significant difference be-
tween two dissolution profiles. Similar results were obtained at pH 7.2 (Table II) indicat-
ing no significant difference between the freshly made liquisolid and aged liquisolid for-
mulations in terms of their DE and MDT values. In order to confirm this conclusion, the
similarity factor (f2) was calculated for freshly prepared ILS-1 as a reference and the
aged ILS-1 as a test formulation. The f2 values were 77 and 95 for release at pH 1.2 and
7.2, respectively, indicating similar dissolution profiles before and after aging for the
tablets at both pH values. We could expect that indomethacin liquisolid tablets main-
tained their initial fast releasing character even after 12 months storage.
It can be concluded that aging has no adverse effect either on the hardness of the
indomethacin liquid solid compacts or on the dissolution profile.
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Fig. 3. Differential scanning calorimetery of silica, Avicel, indomethacin, physical
mixture of a conventional formulation and liquisolid formulation.
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CONCLUSION
Liquisolid formulations were designed to contain liquid medications in powdered
form, thereby possessing mechanisms of drug delivery similar to those of soft gelatin
capsule preparations containing liquids. The results showed that the liquisolid technique
could be a promising alternative technique to increase the dissolution of water insoluble
drugs. The results of DSC and X-ray crystallography ruled out any changes in crystal-
linity of the drug or any interaction between the drug and exipients during the formula-
tion process. It was shown that aging had no significant effects on dissolution profile of
indomethacin liquisolid tablets.
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S A @ E T A K
Teku}insko-~vrsti pripravci kao sredstvo za evaluaciju i pobolj{anje
fizi~kokemijskih svojstava te{ko topljivih lijekova
YOUSEF JAVADZADEH, MOHAMMAD REZA SIAHI, SOLMAZ ASNAASHARI i ALI NOKHODCHI
U radu je ispitivan u~inak teku}insko-~vrstih sustava na pobolj{anje osloba|anja u
vodi netopljivih tvari (indometacina). Koriste}i razli~ita nehlapljiva otapala pripravljeno
je nekoliko teku}insko-~vrstih tableta, a zatim je prou~avan u~inak starenja na osloba-
|anje indometacina. Mogu}e interakcije izme|u indometacina i drugih komponenata
pra}ene su difrakcijom rentgenskih zraka na pra{kastom uzorku (XPD) i diferencijalnom
pretra`nom kalorimetrijom (DSC). Osloba|anje je pra}eno pri dva razli~ita pH, 1,2 i 7,2,
simuliraju}i uvjete u `elu~anoj ili crijevnoj teku}ini. Rezultati pokazuju da je profil oslo-
ba|anja iz teku}insko-~vrstih pripravaka zna~ajno bolji pri pH 1,2 ili 7,2, u usporedbi s
pripravcima dobivenim kompresijom. Pobolj{anje osloba|anja indometacina iz teku}insko-
-~vrstih pripravaka posljedica je pove}anog vla`enja povr{ine ~estica ljekovite tvari. Da bi
se prou~io u~inak starenja na ~vrsto}u pripravaka i osloba|anje ljekovite tvari, teku}insko-
-~vrsti pripravci su uskladi{teni 12 mjeseci na 25 °C/75% relativne vla`nosti. Rezultati
ukazuju da starenje nema zna~ajni u~inak na profil osloba|anja. Pripravci s propilen-
glikolom imaju bolji profil osloba|anja nego pripravci s istom koncentracijom PEG 400
ili Tween 80. DSC i XPD pokazuju da nije do{lo do promjene kristalini~nosti niti do in-
terakcije izme|u indometacina i pomo}nih tvari (Avicel i silikagel) za vrijeme izrade pri-
pravaka.
Klju~ne rije~i: indometacin, teku}insko-~vrsti pripravci, profil osloba|anja, starenje, DSC, XPD
Drug Applied Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Iran
Medway School of Pharmacy, Central Ave., University of Kent and Greenwich, Chatham, Kent, ME4
4TB, United Kingdom
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